Researchers at Sylvester Comprehensive Cancer Center have developed a first-of-its-kind, orally administered drug to disrupt prostate cancer cells’ metabolism and deliver the chemotherapy agent cisplatin directly into treatment-resistant prostate cancer cells. The compound – Platin-L – works in two ways, breaking down a process that malignant prostate cancer cells use to fuel their growth, and delivering cisplatin directly into treatment-resistant cancer cells.